Je-Vax Side Effects
Generic name: japanese encephalitis virus vaccine nakayama
Note: This document contains side effect information about japanese encephalitis virus vaccine nakayama. Some of the dosage forms listed on this page may not apply to the brand name Je-Vax.
Some side effects of Je-Vax may not be reported. Always consult your doctor or healthcare specialist for medical advice. You may also report side effects to the FDA.
For the Consumer
Applies to japanese encephalitis virus vaccine nakayama: subcutaneous powder for suspension
Along with its needed effects, japanese encephalitis virus vaccine nakayama (the active ingredient contained in Je-Vax) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention. It is very important that you tell your doctor about any side effect that occurs after a dose of the vaccine, even if the side effect goes away without treatment. Some types of side effects may mean that you should not receive any more doses of the vaccine.
Get emergency help immediately if the following side effect occurs:Rare
- Swelling of face, lips, eyelids, throat, tongue, hands, or feet
Check with your doctor immediately if any of the following side effects occur while taking japanese encephalitis virus vaccine nakayama:Rare
- tiredness or weakness (severe or unusual)
- wheezing or troubled breathing
Check with your doctor as soon as possible if any of the following side effects occur while taking japanese encephalitis virus vaccine nakayama:More common
- Tenderness, soreness, redness, or swelling at place of injection
- Abdominal pain
- aches or pains in muscles
- chills or fever
- general feeling of discomfort or illness
- itching or skin rash
- nausea or vomiting
- Joint swelling
For Healthcare Professionals
Applies to japanese encephalitis virus vaccine nakayama: subcutaneous powder for injection
The majority of adverse effects associated with Japanese encephalitis vaccine have been local and mild systemic effects. In some studies, less than 1% of adverse events were classified as severe. Side effects reportedly decrease with subsequent injections; however, in some cases reactions have occurred with second or third doses, after uneventful prior doses.
Any allergic and unusual adverse reactions should be reported to the Vaccine Adverse Event Reporting System (VAERS) at 1-800-822-7967 (USA) and to the manufacturer.
Local side effects have included tenderness, redness, swelling in <1% up to 31% of vaccinees. Local soreness and redness reportedly decreases with subsequent injections.
Dermatologic side effects have included rash and urticaria. Some vaccinees had generalized itching without evidence of a rash. Refractory urticaria requiring intravenous steroids has also been reported.
Hypersensitivity or hypersensitivity-like reactions have included hives (0.2%), facial swelling (0.1%), generalized urticaria, angioedema of the extremities, and face, especially the lips and oropharynx, erythema multiforme, erythema nodosum, joint swelling, respiratory distress, hypotension, and collapse.
Nervous system side effects have rarely included encephalitis, encephalopathy, seizures, peripheral neuropathy, transverse myelitis, cranial nerve paresis, cerebellar ataxia, behavior disorder, acute disseminated encephalomyelitis, and Bell's palsy.
Cardiovascular side effects have included fatal myocarditis in a patient who received Japanese encephalitis vaccine and meningococcal vaccine, and sudden death in a patient with a history of hypersensitivity and possible anaphylaxis who also received plague vaccine. Hypotension has been reported in conjunction with allergic-like symptoms.
Gastrointestinal side effects have included nausea, vomiting, and abdominal pain in 10% of vaccinees.
Ocular side effects have included optic neuritis in a patient who received Japanese encephalitis vaccine concurrently with multiple other vaccines.
Respiratory side effects have included dyspnea and wheezing in conjunction with allergic-like symptoms.
Other systemic side effects have included fever, dizziness, flu-like symptoms, headache, myalgia, malaise, and chills in 5% to 10% of vaccinees. Headache and febrile episodes were reported in 15.2% and 5.5%, respectively.
Serious adverse events have included Guillain-Barre syndrome in a patient who had mononucleosis; one case of urticaria, hepatitis, respiratory failure, eosinophilia, and pulmonary effusion and infiltrate; respiratory and renal failure in a patient with acid fast bacilli in sputum and pulmonary infiltrate; and hypertension of unknown etiology in a patient who developed a headache several hours after the first dose. Causality has not been determined.
More Je-Vax resources
Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This information does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective, or appropriate for any given patient. Drugs.com does not assume any responsibility for any aspect of healthcare administered with the aid of information provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.